[Ip-health] Healing an ailing pharmaceutical system: prescription for reform for United States and Canada

Michael H Davis m.davis at csuohio.edu
Thu May 17 11:56:31 PDT 2018

Everything depends on whether Obama is ailing or whether it is effectively hostile. If is the latter, the rather milquetoast remedies suggested cannot possibly help. Since it is admitted that those reforms are politically unlikely, it seems far better to propose the reforms spurred by dean Baker's sharp analysis indicating that publicisation of the Pharma industry is the solution. Anything that includes private profit will lead to waste and corruption. Health is not appropriately a sector for profit oriented institutions.



Prof. Mickey Davis
917/771-0235 (cell)

Mailing Address:
Cleveland State University
2121 Euclid Avenue, LB 234
Cleveland, OH 44115-2214

Campus Location:
Cleveland-Marshall College of Law
1801 Euclid Avenue
Law Building, LB 234

Admitted to practice before the United States Patent and Trademark Office, Reg. No. 45,863

-------- Original message --------
From: "Baker, Brook" <b.baker at northeastern.edu>
Date: 5/17/18 10:03 AM (GMT-05:00)
To: Ip-health at lists.keionline.org
Subject: [Ip-health] Healing an ailing pharmaceutical system: prescription for reform for United States and Canada

Key messages
The US and Canadian pharmaceutical systems are dysfunctional
Costs are exorbitant, commercial goals distort drug development,
misleading promotion fosters misuse, and medications are too often
unaffordable for patients
We propose reforms that would provide universal drug coverage without
fees at the point of use while reducing prices through negotiations with
drug firms and, when needed, compulsory generic manufacture
Innovation would be enhanced through patent reform and by establishing
new public agencies to fund drug development and clinical trials
Drug safety, efficacy, and prescribing quality would be improved by raising
standards for approval and safety monitoring
While the proposals face formidable political obstacles, a popular mandate
exists for pharmaceutical reform in both nations

Professor Brook K. Baker
Northeastern U. School of Law
416 Huntington Ave.
Boston, MA 02115
Honorary Research Fellow, University of KwaZulu Natal
Health GAP (Global Access Project) Senior Policy Analyst
(w) 617-373-3217
(c) 617-259-0760
b.baker at northeastern.edu
Skype:  brook_baker

Ip-health mailing list
Ip-health at lists.keionline.org

More information about the Ip-health mailing list